Who is my brother's keeper?

Clinical and research practices designed by developed countries are often implemented in host nations of the Third World. In recent years, a number of papers have presented a diversity of arguments to justify these practices which include the defence of research with placebos even though best proven...

Full description

Saved in:  
Bibliographic Details
Main Author: Kottow, M. H. (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: BMJ Publ. 2002
In: Journal of medical ethics
Year: 2002, Volume: 28, Issue: 1, Pages: 24-27
Online Access: Volltext (JSTOR)
Volltext (kostenfrei)
Volltext (kostenfrei)

MARC

LEADER 00000caa a22000002 4500
001 1816122718
003 DE-627
005 20230427025715.0
007 cr uuu---uuuuu
008 220908s2002 xx |||||o 00| ||eng c
024 7 |a 10.1136/jme.28.1.24  |2 doi 
035 |a (DE-627)1816122718 
035 |a (DE-599)KXP1816122718 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Kottow, M. H.  |e VerfasserIn  |4 aut 
245 1 0 |a Who is my brother's keeper? 
264 1 |c 2002 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a Clinical and research practices designed by developed countries are often implemented in host nations of the Third World. In recent years, a number of papers have presented a diversity of arguments to justify these practices which include the defence of research with placebos even though best proven treatments exist; the distribution of drugs unapproved in their country of origin; withholding of existing therapy in order to observe the natural course of infection and disease; redefinition of equipoise to a more bland version, and denial of post-trial benefits to research subjects. These practices have all been prohibited in developed, sponsoring countries, even though they invariably have pockets of poverty where conditions comparable to the Third World prevail. Furthermore, the latest update of the Declaration of Helsinki clearly decries double ethical standards in research protocols. Under these circumstances, it does not seem appropriate that First World scholars should propose and defend research and clinical practices with less stringent ethical standards than those mandatory in their own countries. Recent years have witnessed frequent reports of less stringent ethical standards being applied to both clinical and research medical practices, for the most part in the field of drug trials and drug marketing, initiated by developed countries in poorer nations. Still more unsettling, a number of articles have endorsed the policy of employing ethical norms in these host countries, which would be unacceptable to both the legislations and the moral standards of the sponsor nations. Also, these reformulations often contravene the Declaration of Helsinki or one of its updates. This paper is not so much concerned with the actual practices, which have been subjected to frequent scrutiny and publicly decried when gross misconduct occurred. Rather, my concern relates to the approval and support such practices have found in the literature on bioethics from authors who might be expected to use their energy and scholarship to explore and endorse the universalisability of ethics rather than to develop ad hoc arguments that would allow exceptions and variations from accepted moral standards. To this purpose, issue will be taken with arguments in three fields: medical and pharmaceutical practices, research strategies, and local application of research results. 
773 0 8 |i Enthalten in  |t Journal of medical ethics  |d London : BMJ Publ., 1975  |g 28(2002), 1, Seite 24-27  |h Online-Ressource  |w (DE-627)323607802  |w (DE-600)2026397-1  |w (DE-576)260773972  |x 1473-4257  |7 nnns 
773 1 8 |g volume:28  |g year:2002  |g number:1  |g pages:24-27 
856 |3 Volltext  |u http://www.jstor.org/stable/27718816  |x JSTOR 
856 |u https://jme.bmj.com/content/medethics/28/1/24.full.pdf  |x unpaywall  |z Vermutlich kostenfreier Zugang  |h publisher [open (via free pdf)] 
856 4 0 |u https://doi.org/10.1136/jme.28.1.24  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u http://jme.bmj.com/content/28/1/24.abstract  |x Verlag  |z kostenfrei  |3 Volltext 
935 |a mteo 
936 u w |d 28  |j 2002  |e 1  |h 24-27 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4185576552 
LOK |0 003 DE-627 
LOK |0 004 1816122718 
LOK |0 005 20220908053332 
LOK |0 008 220908||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2022-08-02#963EAFD9D5FF5A5ABC6FB3FEFE6E6816175A3779 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 866   |x JSTOR#http://www.jstor.org/stable/27718816 
LOK |0 935   |a ixzs  |a ixrk  |a zota 
OAS |a 1 
ORI |a SA-MARC-ixtheoa001.raw